March 15, 2023 7:46am

Five (5) inherent risk factors: subjectivity, complexity, uncertainty, change, and susceptibility to misstatement due to management bias or fraud.

News: Bellicum Pharmaceuticals (BLCM closed down -$0.09 with an aftermarket of -$0.36 or -41.87%) discontinued its ongoing P1/2 clinical trials evaluating the safety and preliminary efficacy of its trials for BPX-601 - metastatic castration-resistant prostate cancer (mCRPC) and BPX-603 are being discontinued following the assessment of the risk/benefit profile of BPX-601 in combination with rimiducid.

Pre-open Indications: 1 Positive and 5 Negative Indications

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

The 8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on will happen behind the headlines today, not tomorrow or yesterday …

 

Dow futures are DOWN -1.60% or (-510 points), S&P futures are DOWN -1.56% or (-61 point) and NASDAQ futures are DOWN -1.28% or (-158 points) early in the pre-open – so far

Stock futures fell on Wednesday,

European markets were sharply lower,

Asia-Pacific markets rise.

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Futures are falling on Wednesday as pressure on the financial sector increased with shares of Credit Suisse, a Swiss Bank with large U.S. and global operations, tumbling more than 20%.

Tuesday, indexes rallied as crucial inflation data came in line with expectations.

·         The Dow closed UP +336.26 points (+1.06%); the S&P closed UP +64.80 points (+1.68%) while the Nasdaq closed UP +239.31 points (+2.14%).

Economic Data Docket: The Commerce Department will release February’s retail sales print revealing how much was spent at stores, online, and at restaurants. 

·         February’s producer-price index, which measures what suppliers are charging businesses, will also be out.

 

Tuesday’s (3/14) … RegMed Investors’ (RMi) closing bell: “knee jerk reaction with the cell and gene therapy sector closing positive while employee payrolls were protected. The dramatic rush to the upside is marginalized by old uncle algorithms takes his cut.” … https://www.regmedinvestors.com/articles/12871

 

RegMed Investors (RMi) Research Note: Upcoming Q4 earnings reporting dates … https://www.regmedinvestors.com/articles/12830

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … “The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth” … https://www.regmedinvestors.com/articles/12843 --- 24 of 35 (my coverage group)

 

Ebb and flow:

Q1/23 –

March – 3 positive and 7 negative closes

·         February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

·         January – 2 holidays, 11 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative indications:

Tuesday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

·         Beam Therapeutics (BEAM) closed up +$0.38 after Monday’s +$1.62 with a negative -0.81 or -2.37% pre-open indication.

·         Bellicum Pharmaceuticals (BLCM) closed down -$0.09 with a negative aftermarket of -$0.36 or -41.87%) following discontinued trials.

·         BioLife Solutions (BLFS) closed up +$0.80 with a negative -$0.23 or -1.07% aftermarket indication.

·         uniQure NV (QURE) closed up +$0.32 with a negative -$0.40 or -2.01% aftermarket indication.

·         Ultragenyx (RARE) closed down -$0.32 after Monday’s +$2.12 with a negative -$0.56 or -1.38 pre-open indication.

Positive Indications:

Tuesday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

·         MiMedx (MDXG) closed down -$0.12 with a positive +$0.18 or +4.80% aftermarket indication,

 

The BOTTOM LINE: I try to keep it simple and short!

The forever lingering question weighs… the sector’s financial stability as related to economic data, inflation affecting share pricing and capital markets, risks compounded by the Silicon Valley Bank’s (SVB) “fall out” and shifting Fed expectations.

Wednesday’s retail sales release will also dominate the conversation as the Fed’s next meeting rapidly approaches.

Cash is more attractive than equities …!

Also, the rush of Q4 and FY22 earnings to release is STILL on … I do NOT believe there are not a lot of cell/gene therapy companies in position yet – UNTIL earnings (Q4 and FY22) are reported – any breakout is a false hope with the inevitable downside re-occurring.

24 of my 35 covered have reported – 3 yesterday.

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product.

And I can always be WRONG but, I am mostly EARLY!

Upcoming Q4 earnings reporting will present challenges to share pricing.

·         BioLife Solutions (BLFS) 3/16 – Thursday

·         There are more coming – waiting for announcements

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.